Results - Announcements
Neuland Laboratories Ltd share price slipped 0.63% to Rs 19576.05 after the company's net profit witnessed a sharp fall of 65.04% to Rs 51.63 crore, while revenue from operations dropped sharply 29.91% to Rs 449.66 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.72 lakh crore, easing 5.05%. It has marginally improved by 2.16% over last one week and ticked higher by 0.86% in last one month while the market capitalization of Neuland Laboratories Ltd has improved by 1.47% and 1.95% in the same period respectively.
Profit before tax (PBT) of Neuland Laboratories Ltd stood at Rs 68.98 crore in Q3 FY26, crashing by 46.71% year-on-year, and tanking 65.14% quarter-on-quarter. EBITDA came in at Rs 90 crore, plunging by 41.42% YoY and tumbling by 57.99% sequentially.
Total expenses contracted by 14.46% to Rs 380.87 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 215.79 crore, softening by 5.67% YoY, while employee benefits expense was at Rs 101.76 crore, seeing a marginal contraction of 4.39% YoY.
For the TTM ended FY26, revenue from operations jumped by 36.98% to Rs 2022.99 crore, while net profit surged by 39.94% to Rs 364.0 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 32794% to Rs 544.33 crore, and PBT witnessed a strong rise of 41.19% to Rs 488.98 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 346.68 crore in FY26, as against Rs 317.4 crore in FY25.
Neuland Laboratories Ltd rallied 14.14% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 9.87% during the same period.